Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Women 35 to 42 Years Old Undergoing in Vitro Fertilization

Trial Profile

Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Women 35 to 42 Years Old Undergoing in Vitro Fertilization

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Follitropin alfa (Primary)
  • Indications Infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms FIN3002
  • Sponsors FINOX
  • Most Recent Events

    • 10 Feb 2016 Planned number of patients changed from 1106 to 1100 as reported by ClinicalTrials.gov.
    • 10 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
    • 10 Feb 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top